Cyclin E

Cyclin E
Name	Cyclin E
Organism	Human

Cyclin E is a regulatory protein that controls progression through the G1 to S phase transition of the eukaryotic cell cycle. It functions as a regulatory subunit for cyclin-dependent kinase complexes and is conserved across metazoans, playing roles in DNA replication, centrosome duplication, and cell fate decisions. Mutations, dysregulation, or amplification of its encoding genes have been implicated in developmental disorders and numerous cancers.

Structure and Isoforms

Cyclin E is encoded by paralogous genes in vertebrates and exists in multiple isoforms generated by alternative splicing and post-translational processing. Structural studies have compared the cyclin box motif and hydrophobic patch across species using data from research groups at institutions such as Harvard University, Stanford University, Max Planck Society, Cold Spring Harbor Laboratory, and University of Cambridge. Crystal structures of cyclin-associated complexes determined by teams at European Molecular Biology Laboratory and MRC Laboratory of Molecular Biology revealed conserved helical repeats and distinct N-terminal regulatory regions. Isoforms differ in molecular weight and subcellular localization; characterization work cited investigators from National Institutes of Health and collaborations with Massachusetts Institute of Technology, University of California, San Francisco, and Imperial College London. Comparative genomics projects at Broad Institute and Wellcome Sanger Institute have mapped evolutionary divergence among isoforms across model organisms such as Mus musculus, Danio rerio, Drosophila melanogaster, and Caenorhabditis elegans.

Function in Cell Cycle Regulation

Cyclin E forms active kinase complexes that are essential for initiation of DNA synthesis and replication licensing. Foundational studies linking cyclin regulatory waves to cell cycle checkpoints were performed at Rockefeller University, Johns Hopkins University, Yale University, Columbia University, and University of Oxford. The cyclin E–dependent kinase triggers firing of replication origins and coordinates centrosome duplication, with mechanistic insights contributed by laboratories at University of Pennsylvania, University of Chicago, KU Leuven, and ETH Zurich. Work from groups at Salk Institute, University of California, Berkeley, and Princeton University elucidated roles in S-phase entry and interaction with retinoblastoma pathway members characterized earlier by investigators at Cold Spring Harbor Laboratory and National Cancer Institute.

Regulation and Degradation

Regulatory circuits controlling cyclin E abundance and activity involve ubiquitin-mediated proteolysis, phosphorylation, and inhibitory binding proteins. The SCF ubiquitin ligase pathway, studied at Max Planck Institute of Biochemistry, University of Freiburg, and University of Tokyo, targets cyclin E for degradation via F-box proteins discovered through screens at EMBL-EBI and Scripps Research. Checkpoint kinases and CDK inhibitors identified at Instituto Gulbenkian de Ciência, University of Toronto, McGill University, and Karolinska Institutet modulate cyclin E phosphorylation state. Proteasome-mediated turnover was characterized by teams at RIKEN, CNRS, and Los Alamos National Laboratory in collaboration with clinical researchers at Mayo Clinic and Cleveland Clinic.

Role in Development and Differentiation

Cyclin E influences lineage specification, organogenesis, and stem cell dynamics across animals, with developmental phenotypes described in studies from University of Cambridge, University College London, University of Edinburgh, and University of Zurich. Research in model systems—conducted at Max Planck Institute for Developmental Biology, Whitehead Institute, Fred Hutchinson Cancer Center, and University of California, Santa Cruz—demonstrated roles in neuronal differentiation, muscle development, and hematopoietic progenitor proliferation. Developmental genetics work linking cyclin E perturbation to congenital anomalies involved collaborations with clinical centers such as Great Ormond Street Hospital and Boston Children's Hospital.

Involvement in Cancer and Clinical Significance

Aberrant expression, gene amplification, and truncating mutations of cyclin E genes have been associated with tumorigenesis, poor prognosis, and therapeutic resistance. Large-scale cancer genomics initiatives at The Cancer Genome Atlas, International Cancer Genome Consortium, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and MD Anderson Cancer Center have cataloged cyclin E alterations across carcinoma subtypes. Translational research conducted at Stanford Medicine, UCSF Medical Center, Johns Hopkins Hospital, and M.D. Anderson Cancer Center evaluated cyclin E as a biomarker and therapeutic target, exploring CDK inhibitors developed by pharmaceutical companies including Pfizer, Novartis, Roche, and AstraZeneca. Clinical trials coordinated by National Cancer Institute and cooperative groups such as EORTC and NCI-CONNECT assessed outcomes in patients with cyclin E–driven malignancies.

Interactions and Binding Partners

Cyclin E binds cyclin-dependent kinases and numerous regulatory proteins; identification of these interactions involved proteomics centers at EMBL, Broad Institute, Proteomics Core Facility (NIH), and European Proteomics Infrastructure. Key binding partners were mapped in studies from Cold Spring Harbor Laboratory, University of Michigan, Vanderbilt University, and University of Texas MD Anderson Cancer Center, including associations with CDK inhibitors, replication licensing factors, and ubiquitin ligase adaptors. Collaborative interactome projects with groups at Wellcome Trust Sanger Institute and Max Planck Institute of Biochemistry integrated yeast two-hybrid, co-immunoprecipitation, and mass spectrometry datasets.

Experimental Methods and Research Tools

A range of experimental approaches has been used to study cyclin E, from X-ray crystallography and cryo-electron microscopy at Diamond Light Source and European Synchrotron Radiation Facility to single-cell sequencing and live-cell imaging at Broad Institute, Janelia Research Campus, Allen Institute for Brain Science, and Harvard Medical School. Functional genetics using CRISPR/Cas9, RNA interference, and transgenic models came from labs at MIT, UC Berkeley, Cold Spring Harbor Laboratory, and European Molecular Biology Laboratory. High-throughput screening platforms and chemical biology collaborations with Novartis Institutes for BioMedical Research and Genentech have produced small-molecule modulators used in preclinical studies at Fred Hutchinson Cancer Research Center and cancer centers worldwide.

Category:Cell cycle proteins